1. Market Research
  2. > Pharmaceutical
  3. > Pathology Market Trends
  4. > HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2013

HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 47 pages

HIV-Associated Lipodystrophy Syndrome – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for HIV-Associated Lipodystrophy Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-Associated Lipodystrophy Syndrome. HIV-Associated Lipodystrophy Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for HIV-Associated Lipodystrophy Syndrome.
- A review of the HIV-Associated Lipodystrophy Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-Associated Lipodystrophy Syndrome pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for HIV-Associated Lipodystrophy Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-Associated Lipodystrophy Syndrome pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
HIV-Associated Lipodystrophy Syndrome Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome 7
HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Companies 9
HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Development by Companies 15
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development 17
Theratechnologies Inc. 17
Aileron Therapeutics, Inc. 18
HIV-Associated Lipodystrophy Syndrome - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
tesamorelin acetate - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
tesamorelin acetate - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
somatropin - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Leptin - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
mecasermin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
ALRN-5281 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
HIV-Associated Lipodystrophy Syndrome Therapeutics - Drug Profile Updates 34
HIV-Associated Lipodystrophy Syndrome Therapeutics - Discontinued Products 39
HIV-Associated Lipodystrophy Syndrome - Product Development Milestones 40
Featured News and Press Releases 40
Oct 10, 2012: Theratechnologies Provides Follow-up Regulatory Update On Tesamorelin 40
Sep 06, 2012: Aileron Therapeutics Unveils New Therapeutic Drug Program; Appoints Hubert C Chen As Vice President of Clinical Development 41
Jun 22, 2012: Theratechnologies Provides Regulatory Update On Tesamorelin 41
Jun 04, 2012: Theratechnologies Announces Submission Of Marketing Authorization Application For Tesamorelin In Colombia And Venezuela 42
Dec 07, 2011: Theratechnologies To Discontinue COPD Clinical Program And Accelerate Path To Profitability 43
Oct 19, 2011: Theratechnologies Announces Application For Registration Of Tesamorelin In Mexico 43
Aug 31, 2011: Theratechnologies Announces Marketing Authorization Application For Tesamorelin In Brazil 44
Jul 05, 2011: Theratechnologies Announces Filing Of Application For Registration Of Tesamorelin In Israel By Sanofi 44
Jun 06, 2011: Theratechnologies Announces Filing Of European Marketing Authorization Application For Tesamorelin 45
Jun 24, 2010: Theratechnologies Announces Publication Of Combined Tesamorelin Phase III Results In JCEM 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47



List of Tables

Number of Products Under Development for HIV-Associated Lipodystrophy Syndrome, H1 2013 7
Products under Development for HIV-Associated Lipodystrophy Syndrome - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Theratechnologies Inc., H1 2013 17
Aileron Therapeutics, Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
HIV-Associated Lipodystrophy Syndrome Therapeutics - Drug Profile Updates 34
HIV-Associated Lipodystrophy Syndrome Therapeutics - Discontinued Products 39



List of Figures

Number of Products under Development for HIV-Associated Lipodystrophy Syndrome, H1 2013 7
Products under Development for HIV-Associated Lipodystrophy Syndrome - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

 HIV-Associated Lipodystrophy Syndrome-Pipeline Insights, 2015

HIV-Associated Lipodystrophy Syndrome-Pipeline Insights, 2015

  • $ 1 250
  • Industry report
  • May 2015
  • by Delve Insight

Summary DelveInsight’s, HIV-Associated Lipodystrophy Syndrome- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the HIV-Associated Lipodystrophy Syndrome. The main ...

The 2016-2021 World Outlook for Human Immunodeficiency Virus (HIV) Treatments

The 2016-2021 World Outlook for Human Immunodeficiency Virus (HIV) Treatments

  • $ 995
  • Industry report
  • April 2015
  • by ICON Group

This econometric study covers the world outlook for human immunodeficiency virus (HIV) treatments across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential ...

The 2016-2021 World Outlook for HIV/AIDS Confirmatory Tests

The 2016-2021 World Outlook for HIV/AIDS Confirmatory Tests

  • $ 995
  • Industry report
  • April 2015
  • by ICON Group

This econometric study covers the world outlook for HIV/AIDS confirmatory tests across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry ...


Download Unlimited Documents from Trusted Public Sources

Pathology Description

  • July 2015
    56 pages
  • AIDS  

    Digestive Syste...  

  • Africa  

    Ethiopia  

View report >

Pathology Description in the US, Weekly Update

  • July 2015
    12 pages
  • Pathology  

  • United States  

View report >

Pathology Description in Canada

  • July 2015
    25 pages
  • Occupational He...  

  • Canada  

    North America  

View report >

Related Market Segments :

HIV
Dermatological Condition

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.